...
首页> 外文期刊>Planta medica: Natural products and medicinal plant research >A Novel Self-Microemulsifying System for the Simultaneous Delivery and Enhanced Oral Absorption of Curcumin and Resveratrol
【24h】

A Novel Self-Microemulsifying System for the Simultaneous Delivery and Enhanced Oral Absorption of Curcumin and Resveratrol

机译:一种用于同时递送和增强姜黄素和白藜芦醇的口服吸收的新型自我乳胶系统

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The use of curcumin and resveratrol in combination has now become increasingly of interest because of their synergistic effects as therapeutic agents for various diseases, especially cancer. To overcome the poor oral bioavailability of both compounds and improve patient compliance, a novel self-microemulsifying formulation containing curcumin together with resveratrol was developed. Capryol 90, Cremophor EL, and Labrasol were selected as the oil, surfactant, and co-surfactant in the formulation, respectively, based on the solubility study of both compounds. More than 70% and 80% of curcumin and resveratrol, respectively, were released in 20min. The formulation formed a fine oil in water microemulsion with droplet sizes in aqueous media of 15-20 nm. In addition, the formulation containing curcumin and resveratrol showed greater antioxidant activity than that of the formulations with individual compounds, while the cytotoxic activity against HT-29 of the co-formulation (IC50 = 18.25 mu M; curcumin and resveratrol in the ratio 1: 1) was less than the formulation with only curcumin ( IC50 = 30.1 mu M) and only resveratrol ( IC50 = 25.4 mu M). After oral administration to rabbits, the self-microemulsifying formulation containing curcumin together with resveratrol increased the total plasma concentrations of curcumin and resveratrol by 10-fold and 6-fold, respectively, compared to the unformulated combination. This study clearly demonstrated the potential use of the self-microemulsifying formulation for co- delivery, and enhanced oral absorption of poorly watersoluble natural compounds. In addition, the combination was found to produce synergistic antioxidant activity and cytotoxicity against HT-29 cells.
机译:由于其作为各种疾病,尤其是癌症的治疗剂的协同效应,姜黄素和白藜芦醇的使用现在越来越受到兴趣。为了克服两种化合物的口服生物利用度差,提高患者依从性,开发了一种与白藜芦醇一起含有姜黄素的新型自微乳化制剂。基于两种化合物的溶解度研究,分别选择在制剂中作为油,表面活性剂和共表面活性剂选择烷醇纤维素90,Cremophor EL和粘粒醇。分别在20分钟内分别超过70%和80%的姜黄素和白藜芦醇。该配方在水微乳液中形成细油,液滴尺寸为15-20nm。此外,含有姜黄素和白藜芦醇的制剂表现出比具有单个化合物的制剂更大的抗氧化活性,而具有共同制剂的HT-29的细胞毒性活性(IC50 =18.25μm;姜黄素和白藜芦醇的比例1: 1)小于仅具有姜黄素(IC50 =30.1μm)的配方,并且仅白藜芦醇(IC50 =25.4μm)。在口服捕获兔子后,与未形成的组合相比,将含有姜黄素的自微乳化制剂与白藜芦醇一起增加姜黄素和白藜芦醇的总血浆和白藜芦醇的总血浆浓度为10倍和6倍。本研究清楚地证明了潜在使用自我微乳化配方进行共递送,并增强了水溶性天然化合物的口服吸收。此外,发现该组合产生了对HT-29细胞的协同抗氧化活性和细胞毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号